NCT07110883View on ClinicalTrials.gov

A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

August 15, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2028

Conditions
Advanced Solid Tumor
Interventions
DRUG

SYS6023

SYS6023 is a novel antibody-drug conjugate (ADC) targeting HER3, administered via intravenous infusion.

Trial Locations (2)

150000

RECRUITING

Affiliated Tumor Hospital of Harbin, Harbin

200000

RECRUITING

Shanghai Chest Hospital, Shanghai

All Listed Sponsors
lead

CSPC Megalith Biopharmaceutical Co.,Ltd.

INDUSTRY